HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NPD acquisition

This article was originally published in The Rose Sheet

Executive Summary

NPD purchase of market research firm Parkod, including Parkod France and Parkod Europe, will benefit retailers and manufacturers in the perfume industry by reinforcing services in the selective perfumery category, NPD Group says, announcing the acquisition Nov. 23. NPD will leverage Parkod's software, brands and databases in the perfumery segment to strengthen NPD BeautyTrends' own systems and provide expanded services across Europe, the firm adds. Company named Claude Charbit, the former exec VP of European operations for Information Resources, Inc., chairman of Parkod...

You may also be interested in...



Perrigo Oral Care Targets North American Value Tier With High Ridge Brands Acquisition

REACH and Dr. Fresh, as well as Firefly kids’ toothbrushes and mouth rinses featuring popular comic book and cartoon characters, will join Perrigo’s Ranir division under the $113m cash deal, which is subject to federal bankruptcy court approval but expected to close in the 2020 first quarter.

Sold! Tengram Leaves High Ridge Auction With Iconic Brands Including Zest, Alberto VO5

Subject to the approval of a federal bankruptcy court presiding over High Ridge Brands’ Chapter 11 case, private equity firm Tengram will add a raft of personal cleansing and hair-care brands to its portfolio while bringing back former High Ridge CEO James Daniels to head up the collection’s rejuvenation.

Top FDA Officials: Agency Actively Cracking Down On Medical Products With Sham COVID-19 Claims

US FDA commissioner Stephen Hahn and ORA associate commissioner for regulatory affairs Judith McMeekin said in a joint 24 February statement that the agency continues to aggressively monitor the market for any firms selling products with fraudulent COVID-19 prevention and treatment claims. The officials also explained that the FDA has the authority under FDASIA to ask for records from drug manufacturers in lieu of conducting facility inspections. It can't do the same for device companies, however, because no similar provision exists. The FDA had announced on 14 February that it paused all inspections of Chinese manufacturing facilities in the near-term.

UsernamePublicRestriction

Register

RS012641

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel